Jean-Jacques Kiladjian/LinkedIn
Nov 24, 2025, 10:25
Jean Jacques Kiladjian Visits INSERM-supervised CIC 1408 Investigation Center
Jean Jacques Kiladjian, Head of Clinical Research Department of Inserm, shared on LinkedIn:
”A busy day visiting the INSERM-supervised CIC 1408 clinical investigation center in Saint-Etienne during its evaluation by HCERES, showcasing its dynamism and impressive scientific output in clinical pharmacology and public health, with a strong focus on vascular/hemostasis, immunomonitoring, inflammatory diseases (IBD and systemic), vaccinology, population health, paramedical research, and mental health.”
Stay updated with Hemostasis Today.
-
Jan 12, 2026, 04:51Coronary Microvascular Dysfunction and HFpEF․ Prognostic Importance and Therapeutic Insights
-
Jan 12, 2026, 04:16Wolfgang Miesbach on VTE and Cancer: A 20-Year Signal That Can’t Be Ignored
-
Jan 12, 2026, 03:54Francine Freitas Fernandes on Transvaginal US for Pelvic Venous Disorders
-
Jan 12, 2026, 02:58Jara Garcia Ugaldebere Shares STORM-PE Results: Thrombectomy Plus Anticoagulation for Acute High-Risk PE
-
Jan 12, 2026, 02:54Discover the New Blood Project․ Enhanced Search, Browsing, and Learning Resources
-
Jan 12, 2026, 02:54Can Preoperative Iron Status Predict Severe Anemia After Bariatric Surgery?
-
Jan 12, 2026, 02:27Bryce Kerlin to Impact of Advanced Hemostasis/Thrombosis Fellowship Training at Haemophilia Publication
-
Jan 12, 2026, 02:21Martin Haluzík on Compariosn of Cardiovascular Outcomes Between Semaglutide and Dulaglutide Therapies
-
Jan 12, 2026, 01:55Frank Weinz on State-of-the-Art Thromboembolism Prophylaxis